20746-71-8

Basic information

• Product Name: ALLYL-2,3-DI-O-BENZYL-4,6-O-BENZYLIDENE-ALPHA-D-GLUCOPYRANOSIDE
• Synonyms: ALLYL-2,3-DI-O-BENZYL-4,6-O-BENZYLIDENE-ALPHA-D-GLUCOPYRANOSIDE;Allyl2,3-di-O-benzyl-4,6-O-benzylidene-a-D-glucopyranoside
• CAS NO: 20746-71-8
• Molecular Formula: C₃₀H₃₂O₆
• Molecular Weight: 488.57148
• Mol File: 20746-71-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ALLYL-2,3-DI-O-BENZYL-4,6-O-BENZYLIDENE-ALPHA-D-GLUCOPYRANOSIDE(CAS DataBase Reference)
• NIST Chemistry Reference: ALLYL-2,3-DI-O-BENZYL-4,6-O-BENZYLIDENE-ALPHA-D-GLUCOPYRANOSIDE(20746-71-8)
• EPA Substance Registry System: ALLYL-2,3-DI-O-BENZYL-4,6-O-BENZYLIDENE-ALPHA-D-GLUCOPYRANOSIDE(20746-71-8)

Safety Data

• Hazardous Substances Data: 20746-71-8(Hazardous Substances Data)

Usage

Chemical Structure

Contains a sugar molecule (glucopyranoside derivative)

Functional Groups

Allyl and benzyl groups

Properties

Antimicrobial: Due to the presence of allyl and benzyl groups
Antifungal: Also attributed to allyl and benzyl groups

Applications

Pharmaceutical: Studied for potential use in drug development
Medical: Investigated for potential treatments for various diseases

Ongoing Research

Continues to be studied for specific properties and medical applications

Upstream product

• 4163-65-9 per-O-acetyl-α-D-mannopyranose 
• 214490-84-3 Allyl 2,3,4,6-Tetra-O-acetyl-D-mannopyranoside 
• 119111-33-0 (3aS,5aR,8R,9aR,9bS)-4-Allyloxy-2,8-diphenyl-hexahydro-[1,3]dioxolo[4',5':4,5]pyrano[3,2-d][1,3]dioxine 
• 618-31-5 benzylidene dibromide 
• 182212-07-3 α,β-O-allyl-D-mannopyranoside 
• 530-26-7 D-Mannose 
• 100-44-7 benzyl chloride 
• 1056479-53-8 allyl-4,6-O-benzylidene-2,3-di-O-hydroxy-D-mannopyranoside 
• 100-39-0 benzyl bromide 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 48149-72-0 (2S,3R,4S,5R,6R)-2-Allyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 
• 20746-64-9 allyl 4,6-O-benzylidene-α-D-galactopyranoside 

Downstream Products

• 912651-00-4 2,3,6-tri-O-benzyl-D-mannono-1,5-lactone 
• 912650-53-4 3,4,5,7-tetra-O-benzyl-1-deoxy-α-D-gluco-hept-2-ulosyl-(2->4)-2,3,6-tri-O-benzyl-D-mannono-1,5-lactone 
• 912650-56-7 3,4,5,7-tetra-O-benzyl-1-deoxy-α-D-galacto-hept-2-ulosyl-(2->4)-2,3,6-tri-O-benzyl-D-mannono-1,5-lactone 
• 912650-59-0 3,4,5,7-tetra-O-benzyl-1-deoxy-α-D-manno-hept-2-ulosyl-(2->4)-2,3,6-tri-O-benzyl-D-mannono-1,5-lactone 
• 119237-94-4 <2R-(2α,4aβ,5α,6β,7β,7aβ)>-Hexahydro-5-methyl-2-phenyl-6,7-bis(phenylmethoxy)cyclopenta-1,3-dioxin 
• 119237-95-5 <2R-(2α,4aβ,5β,6β,7β,7aβ)>-Hexahydro-5-methyl-2-phenyl-6,7-bis(phenylmethoxy)cyclopenta-1,3-dioxin 
• 119237-93-3 (R)-1,2-Dideoxy-3,4-bis-O-(phenylmethyl)-5,7-O-(phenylmethylene)-D-manno-hept-1-enitol 
• 119111-10-3 Imidazole-1-carbothioic acid O-[(2R,4R,5R)-4-((1R,2R)-1,2-bis-benzyloxy-but-3-enyl)-2-phenyl-[1,3]dioxan-5-yl] ester 

Relevant articles and documents

5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors

(2S,3R,4R,5S,6R)-2-Aryl-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols and (2S,3R,4R,5S,6R)-2-aryl-5-fluoro-5-methyl-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols were discovered as dual inhibitors of sodium glucose co-transporter proteins (

BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

1,3,4,6-Tetra-O-acetyl-2-chloroacetamido-2-deoxy-β-D-glucopyranose as a glycosyl donor in syntheses of oligosaccharides

1,3,4,6-Tetra-O-acetyl-2-chloroacetamido-2-deoxy-β-D-glucopyranose was tested as a glycosyl donor for oligosaccharide synthesis via ferric chloride-catalyzed coupling reaction.Glycosyl acceptors tried (6 in all) were O-benzyl-protected D-galactosides having free OH groups at positions 3 and 4, respectively, and similarly protected glycosides of D-glucose and 2-acetamido-2-deoxy-D-glucose unsubstituted on O-4.Existing syntheses of all the acceptors were improved, in four instances by exploitation of Garegg and Hultberg's cyanoborohydride procedure for the conversion 4,6-O-benzylidene -> 6-O-benzyl .Good to excellent yields of β-linked disaccharides were obtained from the galactoside and glucoside acceptors, but with allyl 2-acetamido-3,6-di-O-benzyl-2-deoxy-α-D-glucopyranoside, stereoselectivity was lost (α:β-ratio 1:2).Allyl and benzyl 2-acetamido-3,6-di-O-benzyl-2-deoxy-β-D-glucopyranosides gave, respectively, the allyl and benzyl β-glycosides of the donor as major products.A mechanism is proposed for this transglycosidation reaction.The N-chloroacetyl groups in the disaccharide products were readily converted into N-acetyl by reduction with zinc-acetic acid.